Clinical Trials Sponsored by Xilio Development, Inc.

Total 1135 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Adult ADHD

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Tourette's Disorder

Germany, United States, Bulgaria, Romania, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Taiwan, Korea, Republic of, Mexico, Canada, Hungary
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Germany, Taiwan, Korea, Republic of, Mexico, Hungary, Bulgaria, Ukraine, Romania, Canada
Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103)

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

Tourette's Disorder (TD)

United States, Canada, Hungary
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation (CADENCE 215)

Atrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

United States, Italy, Germany, Netherlands, Spain, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Pancreatic Cancer

Belgium, Canada, France, Russian Federation, Italy, United States, Australia, Austria, Germany, Romania, Hungary, Poland, United Kingdom, Ireland, Czech Republic
Otsuka Pharmaceutical Development & Commercialization...

Completed

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Hyponatremia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (Pyxis)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Canada, Slovakia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (STEP-D222)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Open-label, Safety and Tolerability Study (STEP 210)

Schizophrenia

United States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR)

Acute Schizophrenia

Korea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tic Disorder | Tourette's Disorder

United States, Canada, Hungary, Italy
Valeritas, Inc.
Integrated Medical Development

Completed

Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting (SIMPLE)

Type 2 Diabetes Mellitus

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE US)

Schizophrenia

United States, Canada
Ironshore Pharmaceuticals and Development, Inc

Completed

A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention-Deficit Hyperactivity Disorder

Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Multiple Myeloma

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

Atopic Dermatitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome

Schizophrenia | Schizoaffective Disorder | Metabolic Syndrome | Bipolar I Disorder

Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole and Effexor XR Drug Interaction Study

Healthy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole and Lexapro Drug Interaction Study

Healthy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (ASPIRE)

Schizophrenia

Korea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
Otsuka Pharmaceutical Development & Commercialization...

Completed

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (ASPIRE)

Schizophrenia

United States, Argentina, Bulgaria, India, Malaysia, Mexico, Philippines, Romania, Russian Federation, Serbia, Slovakia, Taiwan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Congestive Heart Failure

United States
Ironshore Pharmaceuticals and Development, Inc

Not yet recruiting

Ph3 Multicenter, 3wk RDBPC Efficacy, Safety & PK Study of Evening Dosed MPH HCl ER Capsules (HLD200) in Children 4-5 Yr With ADHD

Attention Deficit Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

United States
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Neurobehavioral Disinhibition

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

Binge-Eating Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Attention-deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (STEP-A)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Agitation in Participants With Dementia of the Alzheimer's Type

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

Intermittent Explosive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Atopic Dermatitis

Poland, United States, Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Finland, Germany, Korea, Republic of, United States, Taiwan, Estonia, India, Italy, Mexico
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Schizophrenia

United States

Clinical Trials Sponsored by Xilio Development, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations